Profile data is unavailable for this security.
About the company
Humanwell Healthcare Group Co Ltd is a China-based company principally engaged in the research and development, production and sales of pharmaceuticals. The Company primarily operates its businesses through two segments. Pharmaceutical segment is mainly engaged in the research and development, production and sales of pharmaceutical products and the research and development, production and sales of medical device products, as well as the delivery, distribution and related businesses of pharmaceutical products, providing drugs, devices, medical equipment, reagents, consumables, health products, as well as technology and management services. The Company's products include chemical pharmaceutical preparations, chemical active pharmaceutical ingredients and others. Environmental Protection segment is primarily engaged in environmental protection engineering business.
- Revenue in CNY (TTM)25.56bn
- Net income in CNY1.96bn
- Incorporated1993
- Employees17.68k
- LocationHumanwell Healthcare Group Co LtdNo. 666 Gaoxin AvenueDonghu High-Tech DistrictWUHAN 430075ChinaCHN
- Phone+86 2 787597232
- Fax+86 2 787596393
- Websitehttp://www.humanwell.com.cn
Mergers & acquisitions
Acquired company | 600079:SHH since announced | Transaction value |
---|---|---|
PAION AG | -37.19% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Kangmei Pharmaceutical Co Ltd | 5.21bn | 255.55m | 28.01bn | 4.41k | 109.07 | 3.98 | -- | 5.37 | 0.0185 | 0.0185 | 0.3766 | 0.5079 | 0.3626 | 1.45 | 2.55 | 1,182,457.00 | 1.80 | -17.60 | 2.77 | -32.24 | 20.63 | -72.78 | 4.95 | -101.19 | 0.8398 | -- | 0.0346 | -- | 16.60 | -22.17 | 103.81 | -22.83 | -53.51 | -- |
Hubei Jumpcan Pharmaceutical Co Ltd | 8.92bn | 2.78bn | 28.33bn | 5.23k | 10.15 | 2.01 | -- | 3.18 | 3.03 | 3.03 | 9.71 | 15.27 | 0.5135 | 3.08 | 4.60 | 1,706,101.00 | 16.04 | 16.23 | 20.68 | 20.88 | 78.36 | 82.64 | 31.23 | 24.42 | 3.55 | -- | 0.1024 | 41.76 | 7.32 | 6.02 | 30.04 | 10.83 | -14.70 | 1.11 |
Gan & Lee Pharmaceuticals | 2.95bn | 580.86m | 29.00bn | 4.48k | 49.37 | 2.59 | -- | 9.84 | 0.9773 | 0.9773 | 4.97 | 18.65 | 0.2558 | 0.8458 | 8.94 | 657,602.00 | 5.04 | 8.30 | 5.40 | 8.83 | 72.92 | 85.39 | 19.71 | 26.44 | 6.77 | -- | 0.0005 | 13.65 | 52.31 | 1.78 | 177.37 | -18.30 | 1.50 | -- |
Bluestar Adisseo Co | 14.95bn | 1.09bn | 30.98bn | 2.73k | 28.42 | 1.96 | -- | 2.07 | 0.4064 | 0.4064 | 5.57 | 5.90 | 0.6887 | 5.18 | 8.01 | 5,466,479.00 | 5.03 | 5.28 | 6.07 | 6.94 | 29.20 | 30.31 | 7.30 | 8.76 | 1.16 | 7.83 | 0.1105 | 21.81 | -9.26 | 2.92 | -95.82 | -43.75 | 2.74 | -19.09 |
Xiamen Amoytop Biotech Co Ltd | 2.60bn | 740.69m | 31.68bn | 1.96k | 42.77 | 13.99 | -- | 12.21 | 1.82 | 1.82 | 6.38 | 5.57 | 1.08 | 0.8928 | 6.18 | 1,324,099.00 | 30.73 | 17.96 | 35.90 | 21.02 | 92.71 | 90.48 | 28.54 | 19.17 | 3.60 | -- | 0.0044 | 26.95 | 37.55 | 36.19 | 93.52 | 103.28 | 81.61 | -- |
Humanwell Healthcare Group Co Ltd | 25.56bn | 1.96bn | 34.55bn | 17.68k | 17.47 | 1.93 | -- | 1.35 | 1.21 | 1.21 | 15.87 | 10.95 | 0.6902 | 3.80 | 2.74 | 1,445,825.00 | 7.13 | 6.20 | 13.12 | 12.72 | 45.59 | 42.82 | 10.33 | 9.84 | 1.21 | 12.09 | 0.3171 | 18.87 | 9.79 | 5.65 | -14.07 | -- | 8.25 | -- |
Holder | Shares | % Held |
---|---|---|
Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 53.57m | 3.47% |
China Merchants Fund Management Co., Ltd.as of 30 Sep 2023 | 39.69m | 2.57% |
Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 31.97m | 2.07% |
China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 20.74m | 1.34% |
Zhong Ou Asset Management Co., Ltdas of 30 Sep 2023 | 19.03m | 1.23% |
China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 17.29m | 1.12% |
GF Fund Management Co., Ltd.as of 30 Sep 2023 | 12.83m | 0.83% |
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2024 | 10.84m | 0.70% |
Yinhua Fund Management Co., Ltd.as of 30 Jun 2024 | 10.54m | 0.68% |
Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2024 | 10.23m | 0.66% |